Clinical trial
HIV Candidate Vaccine, ALVAC-HIV-1, Administration in HIV-Negative Adults
NCT00013572 · Walter Reed Army Institute of Research (WRAIR), U.S. Fed · Unknown status
Key facts
| NCT number | NCT00013572 |
|---|---|
| Title | HIV Candidate Vaccine, ALVAC-HIV-1, Administration in HIV-Negative Adults |
| Official title | A Phase I Study of Aventis Pasteur Live Recombinant ALVAC-HIV (vCP205, HIV-1 Env/Gag/Pol) in Seronegative Adults Administered (1) Subcutaneously Via Ex Vivo Transfected, Autologous Dendritic Cells, (2) Intradermally, or (3) Intramuscularly |
| Lead sponsor | Walter Reed Army Institute of Research (WRAIR), U.S. Fed |
| Status | Unknown status |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | HIV Infections, HIV Seronegativity |
| Intervention type | Biological |
| Interventions | ALVAC-HIV MN120TMG (vCP205) |
| Enrollment | 36 |
| First posted | Aug 31, 2001 |
| Last update posted | Jun 24, 2005 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: